Severe or Persistent Side Effects: While mild gastrointestinal symptoms are expected initially, certain symptoms require prompt medical attention
Typically, you may be a candidate for GLP-1 therapy if you meet one of the following criteria: A BMI of 30 or higher, which is classified as obesity
Threshold results show how many participants reached specific levels, such as 5%, 10%, or 15% weight loss
6.1 MASLD and NASH Studies have shown that GLP-1RAs reduce hepatic fat content and improve liver histology in patients with MASLD, decreasing steatosis, ballooning necrosis, and liver enzyme levels
More recently, GLP-1 RA drugs have been approved for weight loss, cardiovascular disease, and chronic kidney disease
The GLP-1R and GIPR pathways both converge on beta cell function through incretin signaling, and retatrutide provides a tool to study the amplified incretin response that occurs when both receptors are activated simultaneously